Navigation Links
New early detection studies of lung cancer in non-smokers launched today
Date:5/4/2009

Government and private sector cancer scientists today launched a research partnership to find biomarkers for lung cancer that develops in people who have never smoked. The research studies are designed to create a better understanding of the biology of lung cancer and to develop a test to detect early-stage lung cancer in lifetime nonsmokers.

The Canary Foundation, a nonprofit organization that funds research in early cancer detection, and the National Cancer Institute (NCI), part of the National Institutes of Health, are sponsoring this multi-institutional effort. NCI's Early Detection Research Network (EDRN) and the Canary Foundation will provide initial funding of $1 million each.

Research has shown that lung cancer in people who have never smoked differs in many ways from the disease in smokers. For example, non-smokers with lung cancer have different tumor tissue structure, gene mutations, and demographic profiles than smokers with lung cancer. "Efforts to study the disease in never-smokers have been limited, and no screening tests or approaches for identifying individuals at increased risk are available today," said Samir Hanash, M.D., Ph.D., of the Fred Hutchinson Cancer Research Center, Seattle, and team leader for Canary Foundation-funded projects. "This inability to recognize non-smokers who are at risk often leads to delays in diagnosis and results in cancer identification at an advanced stage, and this problem is what we're tackling with this new study."

Global estimates suggest that as many as 25 percent of all lung cancers worldwide 15 percent of those in men and 50 percent of those in women are not attributable to smoking. "If you consider lung cancer in never smokers as a separate category, it ranks as the seventh most common cause of cancer deaths worldwide, even before cancers of the cervix, pancreas and prostate," commented Adi Gazdar, M.B.B.S., of the University of Texas Southwestern Medical Center, Dallas, and team leader for the NCI-funded studies.

Using lung cancer cell lines, tissue, and blood specimens, researchers at five of the nation's leading research institutions will undertake a coordinated approach to biomarker discovery using their expertise to study the same sets of specimens by different methods. The researchers will deposit the data in a single repository, and integrate the results to find the most promising biomarkers. Because of this design, this project will also serve as a pilot study to demonstrate the feasibility of the approach and the ability to integrate the data across different platforms. If it is successful, the researchers plan to open the project to additional collaborators from the EDRN.

The NCI-EDRN will fund most of the tumor studies, and the Canary Foundation will provide funding for the cell culture studies.

Projects funded by NCI include:

  • Protein biomarker discovery: In-Depth Proteomic Analysis of Plasmas from Subjects with Lung Cancer Arising in Current, and Never Smokers (Principal Investigator (PI): Hanash)
  • Genome analysis: Mining the Genome and Transcriptome in Lung Cancer from Never Smokers (PI: Gazdar)
  • Cellular alterations: Mitochondrial Mutations in Lung Cancer from Never Smokers (PI: David Sidransky, Johns Hopkins University School of Medicine, Baltimore, Md.)
  • Genome analysis: Genomic Studies of Lung Cancer Arising in Current, and Never Smokers (PIs: Wan Lam and Stephen Lam, British Columbia Cancer Agency, Vancouver, British Columbia)

Projects funded by the Canary Foundation include:

  • Protein biomarker discovery: Proteomic Analysis of Lung Cancer Cell Lines (PI: Hanash)
  • Tumor biomarker discovery: Biomarker Discovery for Lung Cancer in Never Smokers (PI: Gazdar)
  • Genome analysis: Genomic Studies of Lung Cancer Cell Lines from Lung Cancers Arising in Current, and Never Smokers (PIs: Lam and Lam)
  • RNA analysis: MicroRNA Profiles of a Lung Cancer Cell Line Panel (PI: Muneesh Tewari, Fred Hutchinson Cancer Center, Seattle, Wash.)
  • Genome analysis: Genome-Wide DNA Methylation Profiling of Lung Adenocarcinomas from Never Smokers and Current Smokers (PI: Ite Laird-Offringa, University of Southern California, Los Angeles)

"This project is extremely important, both in its approach toward lung cancer detection and in its structure as a multi-institutional, transdisciplinary project funded through a public-private partnership," said John E. Niederhuber, M.D., director of the National Cancer Institute. "Identification of biomarkers, which tell us who is at risk for cancer and help diagnose cancer at the earliest possible stages, is an important priority in cancer prevention research and a key component in efforts to reduce the burden of this disease."


'/>"/>

Contact: NCI Office of Media Relations
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute
Source:Eurekalert

Related biology news :

1. Personalized treatment for early lung cancer
2. Early detection of lung cancer: New data presented at multidisciplinary meeting
3. Google Earth aids discovery of early African mammal fossils
4. Early brain activity sheds new light on the neural basis of reading
5. Early isolation linked to enhanced response to cocaine
6. Early isolation linked to enhanced response to cocaine
7. Early administration of antiretroviral therapy can improve survival
8. Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection
9. Novel lung cancer vaccine shows promise in fighting early-stage lung cancer
10. Early family ties: No sponge in the human family tree
11. Two innovative University of Texas at Austin biologists become HHMI Early Career Scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
(Date:2/23/2017)... ... February 23, 2017 , ... David Nolte, PhD accepted Purdue ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization ... to, and success with, commercializing discoveries from Purdue research. “This award is truly ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift Initiative, Inc , (GGI) ... Compass Research . GGI's mission is to advance global health and highlight the greater ... in honor of each clinical trial volunteer. The vision of GGI is to serve ...
(Date:2/23/2017)... Feb. 23, 2017 Aviva Systems Biology ... the acquisition of GenWay Biotech Incorporated, a protein ... and product offering for both the research and ... growth and enhance capabilities for both entities. GenWay,s 18 ... assays will nicely complement ASB,s objective to become ...
Breaking Biology Technology: